What is the recommended dosing schedule of Nurtec ODT (rimegepant) for acute migraine treatment and for preventive therapy?

Nurtec ODT (Rimegepant) Dosing for Migraine

For acute migraine treatment, take rimegepant 75 mg orally as a single dose when a migraine attack begins; for preventive therapy, take 75 mg every other day on a scheduled basis. 1

Acute Treatment Dosing

The FDA-approved dose for acute migraine is 75 mg taken orally as needed, with a maximum of one dose (75 mg) per 24-hour period. 1

• Do not exceed 18 doses in any 30-day period, as safety beyond this frequency has not been established. 1
• Place the orally disintegrating tablet (ODT) on or under the tongue immediately after opening the blister pack; it dissolves in saliva without additional liquid. 1
• Use dry hands when handling the tablet and do not push it through the foil—peel back the foil covering instead. 1

Clinical Context for Acute Use

• Rimegepant is positioned as a second-line option for moderate-to-severe acute episodic migraine in adults who do not tolerate or have inadequate response to combination therapy of a triptan plus an NSAID (or acetaminophen when NSAIDs are contraindicated). 2
• The 2025 American College of Physicians guideline notes that comparative effectiveness data for gepants (including rimegepant) versus triptan-NSAID combinations show uncertain evidence, but rimegepant has proven efficacy versus placebo. 2
• In a phase 4 trial of adults unsuitable for triptans (due to intolerance, lack of efficacy, or contraindications), 55.9% achieved pain relief at 2 hours with rimegepant versus 32.7% with placebo (difference 23.2%, p < 0.0001). 3

Preventive Treatment Dosing

The FDA-approved dose for episodic migraine prevention is 75 mg taken orally every other day on a scheduled basis. 1

• Administer one tablet every other calendar day, regardless of whether a migraine occurs on that day. 1
• If a migraine attack occurs on a non-scheduled dosing day, you may take an additional 75 mg dose as-needed on that day. 4

Clinical Context for Preventive Use

• Rimegepant is recommended as a later-line preventive option after trials of β-blockers (metoprolol or propranolol), valproate, venlafaxine, or amitriptyline, primarily due to cost considerations (annualized wholesale acquisition cost approximately $5,994 for oral rimegepant versus $500 for generic oral preventives). 5, 2
• In the pivotal 12-week randomized controlled trial, rimegepant every other day reduced mean monthly migraine days by −4.3 days versus −3.5 days with placebo (difference −0.8 days, 95% CI −1.46 to −0.20, p = 0.0099). 6
• A 52-week open-label extension demonstrated sustained efficacy with a mean reduction of 6.2 monthly migraine days and a favorable safety profile similar to placebo. 4
• In adults with documented inadequate response to 2–4 categories of traditional oral preventive medications, rimegepant reduced monthly migraine days by −2.1 days versus −0.5 days with placebo (difference −1.6 days, p < 0.0001). 7

Drug Interactions & Dosing Adjustments

Avoid concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin). 1

• With moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole, verapamil): avoid another dose of rimegepant within 48 hours. 1
• Avoid concomitant use with strong or moderate CYP3A inducers (e.g., rifampin, phenytoin, carbamazepine), which may reduce rimegepant efficacy. 1
• With potent P-glycoprotein inhibitors (e.g., cyclosporine, quinidine): avoid another dose of rimegepant within 48 hours. 1

Safety & Tolerability

Rimegepant is well tolerated with a safety profile similar to placebo in both acute and preventive use. 4, 6, 8

• In the 52-week open-label safety study of 1,800 participants using rimegepant as needed or every other day plus as needed, most adverse events were mild or moderate; the most common were upper respiratory tract infection (8.8%), nasopharyngitis (6.8%), and sinusitis (5.1%). 8
• Serious adverse events occurred in only 0.6% of participants, with none considered definitely related to rimegepant. 8
• No signal of drug-induced liver injury was identified; no participant had ALT or AST >3× upper limit of normal concurrent with total bilirubin >2× upper limit of normal. 4
• Hypersensitivity reactions (including dyspnea and rash) can occur, sometimes days after administration; discontinue rimegepant if hypersensitivity develops. 1

Use with Concomitant Preventive Medications

• Rimegepant can be safely used for acute treatment in patients already taking other preventive migraine medications (e.g., topiramate, β-blockers, CGRP monoclonal antibodies). 9
• In a subgroup analysis of 243 participants using concomitant preventive medications, adverse event rates were similar to those not using preventives (68.7% vs 59.2%), with no new safety signals. 9
• Emerging real-world data suggest that dual CGRP therapy (combining a small-molecule antagonist like rimegepant with a CGRP monoclonal antibody) may reduce headache severity by 20% versus 10% with monotherapy (p = 0.039), though this requires confirmation in randomized trials. 10

Use in Special Populations

• Anxiety and depression: In participants with self-reported anxiety (23.2%) or depression (23.7%), or those using SSRIs (10.1%) or other antidepressants (10.8%), rimegepant showed similar safety and tolerability to the overall population. 11
• Pregnancy and lactation: Rimegepant is not specifically addressed in the 2025 ACP guideline for use during pregnancy; discuss risks and benefits with patients of childbearing potential. 2

Medication-Overuse Headache Prevention

Limit rimegepant use to fewer than 18 doses per month to minimize the risk of medication-overuse headache. 1

• The FDA label establishes a safety threshold of 18 doses per 30-day period for acute treatment. 1
• If migraine attacks are frequent enough to require acute treatment ≥4 days per week, initiate or optimize preventive therapy rather than increasing acute medication frequency. 2

Common Pitfalls & Best Practices

• Underdosing: The effective dose is 75 mg; do not split or reduce the dose. 1
• Exceeding frequency limits: Do not take more than one 75 mg dose per 24 hours or more than 18 doses per month for acute treatment. 1
• Improper storage: Do not remove the ODT from the blister pack until immediately before use; moisture exposure can degrade the tablet. 1
• Premature escalation: Ensure adequate trials of first-line therapies (triptan plus NSAID or acetaminophen) before using rimegepant for acute treatment, unless triptans are contraindicated or not tolerated. 2
• Cost considerations: Rimegepant costs approximately $5,994 annually for preventive use versus $500 for generic oral preventives; verify insurance coverage and discuss cost with patients before prescribing. 2, 5